Host-dependent serum specificity to the V3 domain of HIV-1

Scandinavian Journal of Immunology

Volumn 60, Issue 5, 2004, Pages 471-476

  Nabatov, A A ^a   Masharsky, A E ^b   Verevochkin, S V ^b   Emelyanov, A V ^c   Kozlov, A P ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Biomedical Center   (Russian Federation)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN;

ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; METHODOLOGY; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; SEROTYPE; V3 DOMAIN;

ANTIBODY FORMATION; ANTIBODY SPECIFICITY; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNE SERA; PEPTIDE FRAGMENTS; PHYLOGENY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ANALYSIS, PROTEIN; SEQUENCE ANALYSIS, RNA; SEQUENCE HOMOLOGY; VARIATION (GENETICS);

EID: 8444227784     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01506.x     Document Type: Article

References (27)

1. Gougeon ML, Montagnier L. Apoptosis in AIDS. Science 1993;260:1269-70.
2. Samuelsson A, Sonnerborg A, Heuts N et al. Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1997;13:1031-8.
3. Mohri H, Perelson AS, Tung K et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001;194:1277-87.
4. + T cells go out of stock. Nat Immunol 2000;1:285-9.
5. + T cells but a high proportion of replication-competent provirus copies in asymptomatic human immunodeficiency virus type 1 infection. J Virol 1991;65:2019-23.
6. Harris DP, Koch S, Mullen LM, Swain SL. B cell immunodeficiency fails to develop in CD4-deficient mice infected with BM5: murine AIDS as a multistep disease. J Immunol 2001;166:6041-9.
7. + T cell priming in vivo. J Immunol 1999;162:5695-703.
8. Polyak S, Chen H, Hirsch D et al. Impaired class II expression and antigen uptake in monocytic cells after HIV-1 infection. J Immunol 1997;159:2177-88.
9. Ehrhardt RO, Harriman GR, Inman JK et al. Differential activation requirements of isotype-switched B cells. Eur J Immunol 1996;26:1926-34.
10. Lipman MC. MHC Class II and HIV pathogenesis: lots of data, few conclusions. Eur J Clin Invest 2001;31:926-7.
11. Guermonprez P, England P, Bedouelle H, Leclerc C. The rate of dissociation between antibody and antigen determines the efficiency of antibody-mediated antigen presentation to T cells. J Immunol 1998;161:4542-8.
12. Chong Y, Ikematsu H, Ariyama I et al. Evidence of B cell clonal expansion in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2001;17:1507-15.
13. Muller S, Wang H, Silverman GJ et al. B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV-1 infection. Scand J Immunol 1993;38:327-34.
14. Zwart G, Wolfs TFW, Valk M et al. Characterization of the specificity of the human antibody response to the V3 neutralization domain of HIV-1. AIDS Res Hum Retroviruses 1992;8:1897-908.
15. Cheingsong-Popov R, Osmanov S, Pau CP et al. Serotyping of HIV type 1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization. AIDS Res Hum Retroviruses 1998;14:311-8.
16. Nkengasong JN, Willems B, Janssens W et al. Lack of correlation between V3-loop peptide enzyme immunoassay serologic subtyping and genetic sequencing. AIDS 1998;12:1405-12.
17. Plantier JC, Damond F, Lasky M et al. V3 serotyping of HIV-1 infection: correlation with genotyping and limitations. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:432-41.
18. Nabatov AA, Kravchenko ON, Lyulchuk MG et al. Simultaneous introduction of HIV type 1 subtype A and B viruses into injecting drug users in Southern Ukraine at the beginning of the epidemic in the former Soviet Union. AIDS Res Hum Retroviruses 2002;18:891-5.
19. Tam JP, Zavala F. Multiple antigen peptide. A novel approach to increase detection sensitivity of synthetic peptides in solid-phase immunoassays. J Immunol Methods 1989;124:53-61.
20. Plantier JC, Le Pogam S, Poisson F et al. Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotyping. J Virol 1998;72:677-83.
21. Shchelkanov MI, Iaroslavtseva NG, Nabatov AA et al. [Serotypical stratification of HIV-1 in populations of intravenous drug users in the south/southwestern Ukraine] Serotipicheskaia stratifikatsiia VICh-1, v populiatsii vnutrivennykh narkomanov na iuge/iogovostoke Ukrainy. Vopr Virusol 1998;43:176-82.
22. Lukashov VV, Karamov EV, Eremin VF et al. Extreme founder effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus. AIDS Res Hum Retroviruses 1998;14: 1299-303.
23. Juompan L, Lambin P, Zouali M. Selective alterations of the antibody response to HIV-1. Appl Biochem Biotechnol 1998;75:139-50.
24. Leonard CK, Spellman MW, Riddle L et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373-82.
25. Poignard P, Saphire EO, Parren PW, Burton DR. gp120: Biologic aspects of structural features. Annu Rev Immunol 2001;19:253-74.
26. Steele DJ, Laufer TM, Smiley ST et al. Two levels of help for B cell alloantibody production. J Exp Med 1996;183:699-703.
27. Nakashima I, Isobe K, Yoshida T et al. Allotype-linked immune response genes: roles in network control of the immune system. Exp Clin Immunogenet 1991;8:121-39.